Radiation Oncology Center Data for Linac and Equipment Sales

The Radiation Oncology Equipment Market

Radiation oncology is one of the most capital-intensive specialties in medicine. Linear accelerators (linacs) cost $2-5M each, and proton therapy systems run $100-250M for a full center. About 5,000 radiation oncologists practice across roughly 2,000 centers in the US. Because the equipment is expensive and long-lived, the sales cycle is long, the buying committee is large, and the timing of the purchase matters more than in almost any other device category. A center that just replaced its linac is out of the market for a decade; a center approaching end of life on its equipment is your highest-value prospect.

The buying decision involves the medical director, the chief medical physicist, hospital capital planning, biomedical engineering, and the value analysis committee. Each plays a different role, and a sales motion that engages only one of them tends to stall when another gatekeeper raises an objection late in the process. The data problem, then, is not just finding centers; it is finding the right people inside each center and reaching them at the point in the capital cycle when a purchase is actually possible.

Key Data Fields

Equipment age and vendor

Linacs have 10-15 year useful lives. Centers approaching replacement are primary targets, so equipment age is the single most predictive field you can have. Age estimates come from state radiation-machine licensure and registration records, Medicare cost reports, and public capital announcements. The current vendor (Varian, now part of Siemens Healthineers; Elekta; or Accuray) determines competitive positioning, because selling a replacement to a competitor's installed base is a different motion than defending your own.

Medical director and chief physicist

Both roles must be engaged, and they are not interchangeable. The medical director drives clinical requirements: what techniques the department wants to offer and what patient population it serves. The chief medical physicist drives technical specifications, commissioning, and acceptance testing. A vendor who builds a relationship only with the physician gets blocked on technical grounds, and one who courts only the physicist lacks a clinical champion. Identifying both at every target center, by name, is the core of an effective list.

Treatment technique sophistication

Centers performing IMRT, VMAT, SBRT, SRS, and adaptive radiation therapy have already invested in premium platforms and are the most likely to buy next-generation equipment. Centers still running primarily 3D conformal radiation are less likely to adopt advanced systems in the near term, though they can be longer-horizon prospects as they modernize. Technique mix is visible through hospital service-line pages, accreditation records, and published clinical activity.

Proton therapy interest

There are now more than 45 operational proton therapy centers in the US, according to the National Association for Proton Therapy, with additional sites in development. Centers evaluating proton therapy surface their intent years ahead through feasibility studies, certificate-of-need (CON) applications in states that require them, and public capital-planning announcements. Catching that signal early lets a vendor engage during the planning phase rather than after the specification is locked.

How to Build Radiation Oncology Center Data

Start with NPI taxonomy code 2085R0202X (Radiation Oncology) to define the universe of radiation oncologists. From there, the work is mapping physicians to centers, identifying medical directors and chief physicists by name, and layering equipment age and vendor estimates. Those fields come from state radiation-control program records, Medicare cost reports, hospital capital announcements, ASTRO and AAPM affiliations, and center accreditation data. As with every capital-equipment category, no single source carries all the fields, so accuracy depends on combining sources and verifying each record against current data at the time of delivery, sourced from public NPI registries, business listings, and commercial databases.

Common Targeting Mistakes

The biggest mistake in this category is ignoring the capital cycle and treating all centers as equally addressable. Two-thirds of your effort is wasted if you cannot tell which centers are near replacement. The second mistake is single-threading the deal through the physician and never engaging the chief physicist, which leaves the technical evaluation unmanaged. The third is letting equipment and contact data go stale: medical directors rotate, centers get acquired by larger systems, and a linac that was new three years ago is now three years closer to replacement. For how hospital capital purchases clear procurement, see our GPO and value analysis committee guide, and for the broader oncology landscape see our oncology data guide. Request a sample of Provyx radiation oncology center data with director and physicist identification.